Working… Menu

A Study of Sintilimab Compared With Docetaxel or Pemetrexed as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer After Failure With Platinum-Containing Chemotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03830411
Recruitment Status : Recruiting
First Posted : February 5, 2019
Last Update Posted : June 20, 2019
Information provided by (Responsible Party):
Xin-Hua Xu, China Three Gorges University, Yichang, China

Brief Summary:
This prospective, single-center, randomized, controlled study will evaluate the efficacy and safety of sintilimab compared with docetaxel or pemetrexed as second-line treatment for patients with stage IV nonsquamous non-small cell lung cancer with wild-type EGFR after failure with platinum-containing chemotherapy. Treatment may continue as long as participants are experiencing clinical benefit as assessed by the investigator, i.e., in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression.

Condition or disease Intervention/treatment Phase
Nonsquamous Non-Small Cell Lung Cancer Drug: Sintilimab Drug: Docetaxel Drug: Pemetrexed Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 76 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II, Prospective, Single-center, Randomized, Controlled Study to Investigate the Efficacy and Safety of Sintilimab Compared With Docetaxel or Pemetrexed as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer With Wild-type EGFR After Failure With Platinum-Containing Chemotherapy.
Actual Study Start Date : March 13, 2019
Estimated Primary Completion Date : December 30, 2020
Estimated Study Completion Date : June 30, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Arm Intervention/treatment
Experimental: Arm A: Sintilimab
Participants will receive Sintilimab as long as they continue to experience clinical benefit in the opinion of the investigator until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator.
Drug: Sintilimab
Sintilimab will be administered intravenously at a fixed dose of 200 milligrams (mg) on Day 1 of each 21-day cycle.
Other Name: IBI308

Active Comparator: Arm B: Chemotherapy (Docetaxel or Pemetrexed)
Participants randomized to the chemotherapy arm will receive docetaxel or pemetrexed until disease progression per standard RECIST v1.1 or unacceptable toxicity.
Drug: Docetaxel
Docetaxel 75 milligrams per square meter (mg/m^2) will be administered intravenously on Day 1 of each 21-day cycle.

Drug: Pemetrexed
Pemetrexed 500 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle.

Primary Outcome Measures :
  1. Overall Survival (OS) [ Time Frame: Approximately 21 months ]
    Overall Survival (OS) was defined as the time from the date of randomization to the date of death due to any cause. Data for participants who were not reported as dead at the time of analysis was censored at the date when they were last known to be alive.

Secondary Outcome Measures :
  1. Objective Response Rate (ORR) [ Time Frame: Approximately 21 months ]
    ORR was defined as the percentage of participants with confirmed objective tumor response, complete response (CR) or partial response (PR), as determined by investigator using RECIST v1.1 criteria.

  2. Progression-free survival (PFS) [ Time Frame: Approximately 21 months ]
    PFS was defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first. Disease progression was determined based on investigator assessment using response evaluation criteria In solid tumors (RECIST) v1.1.

  3. Duration of response (DOR) [ Time Frame: Approximately 21 months ]
    DOR was defined as the duration from the first tumor assessment that supports the participant's objective response (CR or PR, whichever is first recorded) to disease progression or death due to any cause, whichever occurs first.

  4. Emergence of adverse events(AEs) [ Time Frame: Approximately 21 months ]
    AEs graded using CTCAE (Version 4.0) criteria.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Volunteer to participate in clinical research; fully understand and know the research and sign informed consent;
  2. Age ≥ 18 years old and ≤ 75 years old, either sex;
  3. Eastern Collaborative Oncology Group Performance status (ECOG PS) 0, 1 or 2;
  4. Has a histologically or cytologically confirmed diagnosis of stage IV (according to the 8th edition of the International Association for the Study of Lung Cancer) nonsquamous NSCLC;
  5. Have at least one measurable lesion as defined by RECIST 1.1;
  6. Has progression of disease after treatment with at least two cycles of a platinum-containing doublet chemotherapy according to RECIST V.1.1;
  7. Patients without activating EGFR mutation;
  8. Normal hepatic function: total bilirubin≤1.5×normal upper limit (ULN); Alanine aminotransferase and Aspartate aminotransferase levels ≤2.5×ULN or ≤5×ULN if liver metastasis is present;
  9. Normal renal function: Creatinine ≤1.5×ULN or calculated creatinine clearance ≥45 mL/min (using Cockcroft/Gault formula to calculate );
  10. Normal hematological function: absolute neutrophil count ≥1.5×109/L, platelet count ≥70×109/L, hemoglobin≥80g/L [no blood transfusion or erythropoietin (EPO) within 7 days] Dependency];
  11. Has a life expectancy of at ≥3 months.

Exclusion Criteria:

  1. ECOG PS >2;
  2. Small cell lung cancer and squamous NSCLC;
  3. EGFR mutation or mutation status unknown;
  4. Known hypersensitivity or allergy to monoclonal antibody;
  5. Prior therapy with an anti-programmed cell death (PD)-1, anti-PD-L1, anti-PD-L2, anti-tumor necrosis factor CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways);
  6. Active autoimmune disease, or a documented history of autoimmune disease;
  7. Treatment with systemic corticosteroids (prednisone≥10mg per day or equivalent dose) or other systemic immunosuppressive medications within 2 weeks prior to the first dose;
  8. Known history or active human immunodeficiency virus (HIV);
  9. Known acute or chronic active hepatitis B (HBV DNA positive) infection or acute or chronic active hepatitis C (HCV antibody positive and HCV RNA positive) infection;
  10. Interstitial lung disease, or history of pneumonitis requiring systemic steroids for treatment;
  11. Active or poorly controlled severe infection;
  12. Have serious cardiovascular disease: Symptomatic congestive heart failure (New York Heart Association grade III-IV), unstable angina pectoris, unstable arrhythmia, myocardial infarction or cerebrovascular accident within 3 months before randomization;
  13. Received thoracic radiation therapy of >30 Gy within 6 months prior to first dose of study drug;
  14. Completed palliative radiotherapy within 7 days prior to first dose of study drug;
  15. Pregnant or lactating women.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03830411

Layout table for location contacts
Contact: Xinhua Xu, Master +8613986747496 ext +8613986747496
Contact: Yan Wang, Master +8615997550081 ext +8615997550081

Layout table for location information
China, Hubei
Department of Medical Oncology, Central Hospital of Yichang City, the First Clinical Medical College of Three Gorges University Recruiting
Yichang, Hubei, China, 443003
Contact: Xinhua Xu    +8613986747496 ext +8613986747496   
Sponsors and Collaborators
Xin-Hua Xu

Layout table for additonal information
Responsible Party: Xin-Hua Xu, professor, China Three Gorges University, Yichang, China Identifier: NCT03830411     History of Changes
Other Study ID Numbers: CTGU1901
First Posted: February 5, 2019    Key Record Dates
Last Update Posted: June 20, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Xin-Hua Xu, China Three Gorges University, Yichang, China:
nonsquamous non-small-cell lung cancer
wild-type EGFR
second-line treatment
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors
Folic Acid Antagonists
Nucleic Acid Synthesis Inhibitors